• October 18, 2019

ImaginAb Enrolls First Patient at the University of Alabama at Birmingham in On-going "Base Line/On Therapy" (BOT) Phase II Clinical Trial - Odessa American: Business

e-Edition Subscribe

ImaginAb Enrolls First Patient at the University of Alabama at Birmingham in On-going "Base Line/On Therapy" (BOT) Phase II Clinical Trial

Font Size:
Default font size
Larger font size

Posted: Wednesday, September 25, 2019 6:30 am | Updated: 7:01 am, Wed Sep 25, 2019.

LOS ANGELES, Sept. 25, 2019 /PRNewswire/ -- ImaginAb Inc., a clinical-stage immuno-oncology imaging company, today announces it has enrolled its first patient for the Phase II clinical trial of its lead product CD8 tracer, 89Zr-Df-IAB22M2C, at the O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham (UAB). This study is a collaboration between UAB's Division of Hematology and Oncology and Division of Molecular Imaging and Therapeutics, reflecting UAB's commitment to world-class research and clinical care.

89Zr-Df-IAB22M2C is a first in class imaging agent that visualizes the immune system using non-invasive, whole-body in vivo PET imaging of CD8 T cells. Using its 'Minibody' platform, ImaginAb's technology targets and visualizes CD8+ T-cells to provide highly-specific, quantitative assessment of the immunological status of each cancer lesion within a patient, enabling treatment to be tailored quickly and specifically to the needs of that patient.

UAB is one of ImaginAb's active clinical sites conducting Phase II baseline/on-treatment clinical trials investigating the utility of ImaginAb's CD8 tracer, 89Zr-Df-IAB22M2C, to image CD8 T cells before (baseline) and after (on-treatment) cancer patients receive immunotherapy-based treatment.

Ian Wilson, CEO of ImaginAb, said: "ImaginAb's goal is to provide target-specific imaging agents to predict, inform, monitor and enable the treatment of cancer more effectively. We are delighted to have enrolled and imaged our first patient in this ongoing clinical study at UAB, a world-renowned research center in Nuclear Medicine and Molecular Imaging."

The trial will enroll advanced and metastatic cancer patients and will study the correlation of imaging signals observed using ImaginAb's CD8+ T cell ImmunoPET imaging agent, standard-of-care scans, and immunohistochemistry analysis of CD8 in biopsied tissues. The trial will also measure changes in CD8+ T-cell distribution before and after immuno-oncology therapies.

The ImaginAb team will be at the European Society for Medical Oncology ESMO Congress 2019 at Fira Gran Via, Barcelona from September 27 to October 1, 2019. Dr. Anna Wu, Chief Scientific Advisor, and Board member and Dr. Toni Ribas, Ph.D., ImaginAb Science Advisory Board Member and President-Elect for The American Association for Cancer Research (AACR), will be attending and hosting meetings. In addition, ImaginAb's commercial team led by Ivan Plavec, Chief Business Officer (CBO), will be hosting meetings and available at the ImaginAb Booth #477.

For further information please contact:

ImaginAb Ian Wilson Email: info@imaginab.com Phone: +1 310 645 1211

Optimum Strategic Communications Mary Clark, Supriya Mathur, Manel Mateus Email: imaginab@optimumcomms.com Phone: +44 20 3950 9144

About ImaginAb

ImaginAb Inc. is an immuno-oncology imaging company focused on providing actionable insight into patient selection and treatment progress for cancer immunotherapy, enabling precision medicine. ImaginAb engineers antibody fragments called minibodies that maintain the exquisite specificity of full-length antibodies while remaining inert in the body. Used with widely available PET scan technology, these novel minibodies illuminate high-value molecular targets, providing physicians with a whole-body picture of immune activity. ImaginAb is also developing a pipeline for other targets in oncology. ImaginAb's products have the potential to improve patient care and lower healthcare costs. The Company is backed by top tier venture capital firms and strategic corporate firms including The Parker Institute for Cancer Immunotherapy, Nextech Invest, Adage Capital, The Cycad Group, Merck (MSD) Pharma, Novartis Bioventures and Jim Pallotta of the Raptor Group.

For more information about ImaginAb's pipeline and technology, visit www.imaginab.com.

About the University of Alabama at Birmingham

Known for its innovative and interdisciplinary approach to education at both the graduate and undergraduate levels, the University of Alabama at Birmingham is the state of Alabama's largest employer and an internationally renowned research university and academic medical center; its professional schools and specialty patient-care programs are ranked consistently among the nation's top 50. Learn more at www.uab.edu and www.uabmedicine.org. UAB: Powered by will.

View original content to download multimedia: http://www.prnewswire.com/news-releases/imaginab-enrolls-first-patient-at-the-university-of-alabama-at-birmingham-in-on-going--base-lineon-therapy-bot-phase-ii-clinical-trial-300924871.html

SOURCE ImaginAb, Inc.

© 2019 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Odessa, TX

Current Conditions

Humidity: 59%
Winds: S at 15mph
Feels Like: 62°

Your Extended Forecast


High 83°/Low 56°
A few clouds. Lows overnight in the mid 50s.


High 87°/Low 54°
Sunshine. Highs in the upper 80s and lows in the mid 50s.


High 80°/Low 54°
Abundant sunshine. Highs in the low 80s and lows in the mid 50s.
Online Features

Pet Central


Having a pet is a lot of responsibility, and we’ll help by giving you lots of tips and tricks! More >>



Our fitness articles will help teach you how to work out with gym- and home-based exercises. More >>



Enjoy the crosswords challenge in our free daily puzzles, from the harder Sunday crossword to the quicker daily. More >>



Every Sudoku has a unique solution that can be reached logically. Enter numbers into the blank spaces so that each row, column and 3x3 box contains the numbers 1 to 9. More >>

  • ALL-ACCESS: Subscribe to our e-edition and premium website at myoaoa.com.
    You can read your daily newspaper without taking a walk to the driveway.
    Look back at yesterday's newspaper, or issues from months ago with our archive feature.
    Call circulation at 432-337-7314 to sign up today.